Drug-resistant Streptococcus pneumoniae infections: Clinical importance, drug treatment, and prevention

Seminars in Respiratory Infections

Volumn 16, Issue 3, 2001, Pages 186-195

  Kellner, James D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFACLOR; CEFDINIR; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CHLORAMPHENICOL DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; LORACARBEF; MEROPENEM; OFLOXACIN; PENICILLIN DERIVATIVE; RIFAMPICIN; SPARFLOXACIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; DISEASE SEVERITY; HIGH RISK POPULATION; HOSPITALIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; MENINGITIS; MORTALITY; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

AGE FACTORS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HUMANS; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034837680     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2001.25624     Document Type: Review

References (46)

1. The pneumococcal problem
2. Pneumococcal bacteremia in Charleston County, a decade later
3. Pneumococcal polysaccharide vaccine efficacy
4. Immunization policies and vaccine coverage among adults. The risk for missed opportunities
5. The crisis in antibiotic resistance
6. Emergence of vancomycin tolerance in Streptococcus pneumoniae
7. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae
8. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta
9. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
10. Geographic variation in penicillin resistance in Streptococcus pneumoniae - Selected sites, United States, 1997
11. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States
12. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
13. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model
14. Risk factors for invasive pneumococcal disease in children: A population-based case-control study in North America
15. Antibiotic-resistant pneumococcal disease in South African children
16. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance
17. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci
18. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
19. Infections caused by erythromycin-resistant Streptococcus pneumonia: Incidence, risk factors, and response to therapy in a prospective study
20. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence
21. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
22. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae
23. Therapy for children with invasive pneumococcal infections
24. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin
25. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children
26. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
27. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
28. Community-acquired pneumonia in adults: Guidelines for management
29. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital
30. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
31. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995
32. Treatment of pneumococcal pneumonia
33. The drug-resistant pneumococcus: Clinical relevance, therapy, and prevention
34. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in isolates of Streptococcus pneumoniae
35. Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with high dosage cefotaxime
36. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis
37. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
38. The bacteriologic efficacy of 1-day versus 3-day intramuscular ceftriaxone in the treatment of non-responsive acute otitis media
39. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
40. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): A strategy from the DRSP Working Group
41. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
42. Effectiveness of a pneumococcal vaccination program in preventing invasive pneumococcal disease
43. Vaccination against colonizing bacteria with multiple serotypes
44. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
45. Efficacy of a pneumococcal conjugate vaccine against acute otitis media